Refill rate by surgical specialty. by Wali U. Pirzada (22278071)

“…No significant difference was observed in the mean percentage of prescribed MMEs leftover between the two cohorts (Orthopaedic 47% vs. …”

Noncontinuous data on opioid use. by Wali U. Pirzada (22278071)

“…No significant difference was observed in the mean percentage of prescribed MMEs leftover between the two cohorts (Orthopaedic 47% vs. …”

Phosphorylation status of myofilament proteins prepared from Epac1TG. by Yoshiki Ohnuki (576298)

Fig 1 - Fusing multisensory signals across channels and time by Swathi Anil (17382903)

Data Sheet 1_Exploring the glucose-lowering and anti-inflammatory immune mechanism of artemether by AMPK/mTOR pathway and microbiome based on multi-omics.docx by Tao Jiang (28401)

Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts. by Yoshiki Ohnuki (576298)

Epac activation increased RLC phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Joint Efficiency (%) of ABS Polymers at 800 rpm and 1200 rpm. by Shaheer Ahmed Khan (17797647)

Subjects:

Schematic of fixture. by Shaheer Ahmed Khan (17797647)

Subjects: